Anti-Shigella flexneri 2a, LPS (SHIG-3914)
Anti-Shigella flexneri 2a, LPS (SHIG-3914)
Product No.: S244
- -
- -
Clone SHIG-3914 Target LPS Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Isotype Mouse IgG1 Applications ELISA , IF |
- -
- -
Antibody DetailsProduct DetailsReactivity Species Shigella flexneri Host Species Mouse Product Concentration ≥1.0 mg/ml Purity ≥90% Formulation Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations. Storage and Handling This purified antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA: 1:20-1:200, IF: 1:10-1:50 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Anti-Shigella flexneri (Clone SHIG-3914) is specific for the LPS of Shigella flexneri 2a and displays no cross reactivity for Shigella flexneri 1a, 3a, 4a, 5a, 6, S. sonnei, S. dysenteriae, S. boydii, Citrobacter, Salmonella (mix) or E. coli (mix). Matched Pair Best ELISA pair (capture/detection), SHIG-8964/SHIG-3914 Background Shigella flexneri serotype 2a is a specific strain of Shigella flexneri responsible for causing shigellosis, a prominent global gastrointestinal infection. Serotype 2a holds clinical importance due to its prevalence and virulence. Shigella flexneri 2a infections often lead to severe symptoms such as bloody diarrhea, abdominal cramps, and fever1. The lipopolysaccharides (LPS) on the bacterial cell surface play a pivotal role in its pathogenicity by contributing to adhesion, immune evasion, and triggering inflammatory responses in the host. The bacterium's ability to invade the colonic epithelium leads to localized inflammation and tissue damage, causing the characteristic symptoms of shigellosis. Recently, there have been reports of increased transmission of extensively drug-resistant (XDR) Shigella spp. through sexual activity2. Antigen DetailsResearch Area Bacteria . Category B Pathogens . Infectious Disease . Matched Pair . IVD Raw Material References & Citations1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases. Link
2. Caldera J, Yang S, Uslan DZ. Extensively Drug-Resistant Shigella flexneri 2a, California, USA, 2022. Emerging Infectious Diseases. 2023;29(7):1473-1475. doi:10.3201/eid2907.230465. Technical Protocols IF |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
